Angioedema
Drug research and approvals for angioedema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 23 studies of angioedema are recruiting on ClinicalTrials.gov, Health Canada has authorized 43 drug trials for it since 2013, FDA has 16 approved and 9 open orphan designations naming it, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 23
- Trials authorized in Canada: 43
- FDA orphan approvals: 16
- EU medicines: 9
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With…NCT07654829 · Phase 4 · KalVista Pharmaceuticals, Ltd. · starts Aug 17, 2026
- Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdemaNCT07448181 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Feb 23, 2026
- A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaNCT07445087 · Not reported · Takeda · starts Sep 21, 2026
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499 · Phase 3 · ADARx Pharmaceuticals, Inc. · starts Apr 2, 2026
- Deep Phenotyping of CIndUNCT07359430 · Not reported · Centre for Human Drug Research, Netherlands · starts Jan 21, 2025
- Donidalorsen Treatment in Children With Hereditary AngioedemaNCT07298447 · Phase 3 · Ionis Pharmaceuticals, Inc. · starts Apr 21, 2026
- A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary AngioedemaNCT07293364 · Not applicable · Takeda · starts May 12, 2026
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of…NCT07266805 · Phase 3 · Pharvaris Netherlands B.V. · starts Oct 16, 2025
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsNCT07046806 · Phase 1 / Phase 2 · Institute for Asthma and Allergy · starts Mar 10, 2025
Approved 3
- CarbinoxamineHistamine H1 receptor antagonist
- DexchlorpheniramineHistamine H1 receptor antagonist
- EpinephrineAdrenergic receptor agonist
Phase 3 5
- IcatibantBradykinin B2 receptor antagonist
- LanadelumabPlasma kallikrein inhibitor
- OmalizumabIg epsilon chain C region inhibitor
- ClemastineHistamine H1 receptor antagonist
- Human C1-esterase inhibitorPlasma kallikrein inhibitor
Phase 2 2
- EcallantidePlasma kallikrein inhibitor
- DupilumabInterleukin-4 receptor subunit alpha antagonist
Phase 1 or earlier 2
- BerotralstatPlasma kallikrein inhibitor
- Sebetralstat
How its trials ended
188 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 70 whose ending is known, 77% met their primary endpoint, 1% missed it and 21% stopped early.
- Completed, result not reported7037%
- Met its primary endpoint5429%
- Ongoing4122%
- Status unknown74%
- Stopped: other or unclear53%
- Stopped: lack of efficacy42%
- Stopped: sponsor or business decision32%
- Stopped: enrollment or feasibility21%
- Missed its primary endpoint11%
- Stopped: funding11%
| Apr 7, 2026 | A phase 3 extension study of sirna targeting of prekallikrein with ADX-324 in participants with hereditary angioedemaOnvuzosiran (ADX-324) | ADARx Pharmaceuticals | Pending |
| Dec 3, 2025 | An open-label study of donidalorsen in pediatric patients age 2 to less than 12 years old with hereditary angioedemaDonidalorsen (ISIS721744) | Ionis Pharmaceuticals | Closed |
| Sep 26, 2025 | Phase 3 trial to evaluate the long-term safety and efficacy of navenibart in participants with hereditary angioedema – orbit-expanseNavenibart | Astria Therapeutics | Ongoing |
| Sep 25, 2025 | A phase 3, randomized, double-blind, placebo controlled study of sirna targeting of prekallikrein with ADX-324 in participants with hereditary angioedemaOnvuzosiran (ADX-324) | ADARx Pharmaceuticals | Ongoing |
| Sep 19, 2025 | A phase 3, randomized, double-blind, placebo-controlled, 3-part study to evaluate the efficacy and safety of orally administered deucrictibant xr tablet for…Deucrictibant (PHA-022121) | Pharvaris Netherlands B.V. | Pending |
| Jul 29, 2025 | An open-label study to provide berotralstat access to subjects with type i and ii hereditary angioedema who were previously enrolled in berotralstat studiesBerotralstat (BCX7353) | BioCryst Pharmaceuticals | Closed |
| Jul 10, 2025 | Post study access of CSL312 (garadacimab) for the routine prevention of hereditary angioedema (HAE) attacks in adult and adolescent participants (¿ 12 years…CSL312 (garadacimab) | CSL | Pending |
| May 13, 2025 | Post study access of CSL312 (garadacimab) for the routine prevention of hae attacks in pediatric participants (2-11 years old) with hereditary angioedema (HAE)…Garadacimab (CSL312) | CSL | Ongoing |
| Mar 19, 2025 | Phase 3, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of navenibart in participants with hereditary…Navenibart (STAR-0215) | Astria Therapeutics | Ongoing |
| Jan 14, 2025 | A phase 4 open-label study to evaluate the safety after switching to CSL312 (garadacimab) from current prophylactic hae treatment in subjects with hae ¿ 12…CSL312 (garadacimab) (factor xiia antagonist monoclonal antibody) | CSL | Closed |
| Dec 11, 2025 | OrladeyoProphylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older | BioCryst Pharmaceuticals, Inc. | Approved |
| Aug 21, 2025 | DawnzeraProphylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older | Ionis Pharmaceuticals | Approved |
| Jul 3, 2025 | EkterlyTreatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older | KalVista Pharmaceuticals Ltd | Approved |
| Jun 16, 2025 | AndembryProphylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older | CSL Behring | Approved |
| Feb 3, 2023 | TakhzyroProphylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Dec 3, 2020 | Orladeyo™Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older | BioCryst Pharmaceuticals, Inc. | Approved |
| Sep 24, 2020 | HaegardaHAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary… | CSL Behring LLC | Approved |
| Aug 23, 2018 | TakhzyroProphylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Jun 20, 2018 | CinryzeCINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric… | Takeda Development Center Americas, Inc. | Approved |
| Jun 22, 2017 | HaegardaFor routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. | CSL Behring LLC | Approved |
| Jul 16, 2014 | RuconestTreatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients. | Pharming Group N.V. | Approved |
| Mar 28, 2014 | KalbitorTreatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Aug 25, 2011 | FirazyrTreatment of acute attacks of hereditary angioedema in adults 18 years of age and older | Takeda Development Center Americas, Inc. | Approved |
| Dec 1, 2009 | KalbitorTreatment of acute attacks of hereditary angioedema in patients 16 years of age and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Oct 8, 2009 | BerinertTreatment of acute attacks of hereditary angioedema. | CSL Behring LLC | Approved |
| Jan 19, 2026 | DawnzeraDonidalorsen | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
| Sep 17, 2025 | EkterlySebetralstat · orphan | Kalvista Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Feb 10, 2025 | AndembryGaradacimab | CSL Behring GmbH | EMA ↗ |
| Jul 16, 2021 | Icatibant AccordIcatibant · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Apr 30, 2021 | OrladeyoBerotralstat | Neopharmed Gentili Ireland Limited | EMA ↗ |
| Nov 22, 2018 | TakhzyroLanadelumab · orphan | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
| Jun 15, 2011 | CinryzeC1 inhibitor (human) | Takeda Manufacturing Austria AG | EMA ↗ |
| Oct 28, 2010 | RuconestConestat alfa | Pharming Group N.V. | EMA ↗ |
| Jul 11, 2008 | FirazyrIcatibant | Takeda Pharmaceuticals International AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA